Body Protection Compound

$149.99
/
Tax included.
Only 1247 items in stock!

Body Protection Compoundhas been studied for a variety of topics and has shown to be helpful in many areas such as: tendinopathy, gastric ulcers, general inflammation, and even neuroprotection. Body Protection Compound seems to work by interacting with our cells’ systems that are responsible for growth and repair, thus helping the body to heal itself.

Body Protection Compound has also been shown to be beneficial in supporting the healing of gastric ulcers. Gastric ulcers are a type of peptic ulcer that develops in the lining of the stomach. They are a common and often painful condition that can be difficult to treat. However, Body Protection Compound has been shown to support healing of gastric ulcers and improve symptoms.

One of the best things about Body Protection Compound is that it is orally bioavailable, particularly the arginate salt we use, is extremely stable.   We wanted to make sure that oral bioavailability was maximized which is why we included a molecule called SNAC in our formulation.

Salcaprozate sodium, or SNAC, is one of the most advanced intestinal permeation enhancers that have been tested in clinical trials for oral delivery of macromolecules. It was originally designed for the oral delivery of insulin. In one study, SNAC increased the absorption of a peptide (a short chain of amino acids) by nine-fold without affecting tight junctions. 

Healthgevity's formulation includes an optimal ratio of salcaprozate sodium to our active ingredients. This combination results in exceptional oral absorption of this combination without compromising its stability or efficacy.


REFERENCES

Body Protection Compound:

  • Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022; 10(12):3221. https://doi.org/10.3390/biomedicines10123221
  • Seiwerth, Sven et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Current pharmaceutical design vol. 24,18 (2018): 1972-1989. doi:10.2174/1381612824666180712110447
  • Gwyer, Daniel et al. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and tissue research vol. 377,2 (2019): 153-159. doi:10.1007/s00441-019-03016-8
  • Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010
  • Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. doi:10.2174/1570159x13666160502153022
  •  Seiwerth, S., Sikiric, P., Grabarevic, Z., Zoricic, I., Hanzevacki, M., Ljubanovic, D., … Kolega, Z. (1997). BPC 157’s effect on Healing. Journal of Physiology Paris, 91(3–5), 173–178. https://doi.org/10.1016/S0928-4257(97)89480-6

Salcaprozate sodium (SNAC):

  • Twarog, Caroline et al. “Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10).” Pharmaceutics vol. 11,2 78. 13 Feb. 2019, doi:10.3390/pharmaceutics11020078
  • Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharm Sin B. 2021 Aug;11(8):2416-2448. doi: 10.1016/j.apsb.2021.04.001. Epub 2021 Apr 29. PMID: 34522593; PMCID: PMC8424290.
  • Aroda, V.R., Blonde, L. & Pratley, R.E. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord 23, 979–994 (2022). https://doi.org/10.1007/s11154-022-09735-8